Route 92 Medical

Route 92 Medical develops catheter-based technologies for the treatment of acute ischemic stroke and other neurovascular conditions. Founded by physicians, the company applies engineering and product design to problems in neurointervention, with the stated aim of improving outcomes for patients undergoing neurovascular procedures. It is based in the United States and collaborates with neurovascular clinicians worldwide.

Its product portfolio includes the FreeClimb Catheter Systems, intended to help clinicians rapidly restore blood flow to the brain after acute ischemic stroke, and the HiPoint Reperfusion System, which features the Monopoint Approach. The HiPoint 88 Reperfusion System is a super-bore catheter designed for direct aspiration of large vessel occlusions in the neurovasculature; it is described as the first and only FDA-cleared super-bore 0.088-inch catheter for that indication.

The clinical context is substantial. Stroke affects roughly 16m people globally each year and kills about 6m. In the United States, more than 800,000 patients a year experience acute ischemic stroke, at an annual healthcare cost of $104bn. Route 92 Medical's technical work spans neurovascular intervention, catheter-based medical devices, reperfusion and aspiration thrombectomy technology, and neurointervention engineering, with an emphasis on differentiated solutions for clinical success.